CAS NO: | 145599-86-6 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally activeHMG-CoA reductaseinhibitor, with aKiof 1.3 nM/L. Cerivastatin reduces low-density lipoproteincholesterollevels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly byRhoAinhibition, and has anti-cancer effect[1][2][3]. | ||||||||||||||||||||||||||||||||
IC50& Target | Ki: 1.3 nM/L (HMG-CoA reductase)[1][2][3] | ||||||||||||||||||||||||||||||||
体外研究 (In Vitro) | Cerivastatin (5-50 ng/mL; 3 days; MDA-MB-231 cells) treatment induces a dose-dependent decrease in cell proliferation of MDA-MB-231 cells (up to 40% inhibition at 25 ng/mL)[1]. Cell Proliferation Assay[1]
Cell Cycle Analysis[1]
Western Blot Analysis[1]
RT-PCR[1]
| ||||||||||||||||||||||||||||||||
体内研究 (In Vivo) | Cerivastatin is well absorbed, reaching maximal plasma levels in 1-3 hours following oral dosing. In the circulation, Cerivastatin is highly bound to plasma proteins (99.5%), with an elimination half-life of 2-4 hours. Cerivastatin is metabolized predominantly in the liver to three polar metabolites. Two of these metabolites are active, but to a lesser extent compared to parent drug, and the third metabolite is inactive. Plasma concentrations of all metabolites are substantially lower than those of the parent drug. Elimination of metabolites is via the urine (20-25%) and feces (66-73%), while essentially no parent compound is excreted[2]. | ||||||||||||||||||||||||||||||||
分子量 | 459.55 | ||||||||||||||||||||||||||||||||
Formula | C26H34FNO5 | ||||||||||||||||||||||||||||||||
CAS 号 | 145599-86-6 | ||||||||||||||||||||||||||||||||
中文名称 | 西立伐他汀 | ||||||||||||||||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||||||||||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |